Indian generic drugmakers face potential US tariff shock from 2028
Proposed US tariffs of 100% from August 2028 and 200% from August 2029 could pressure India’s $9.7 billion pharma export market, though low-cost generics may retain an edge. Manufacturers are weighing US production, market diversification and lower reliance on Chinese inputs.
Trump plans tariffs of up to 200% on imported generics from 2028-29, exposing Indian drugmakers heavily. Indian medicines may remain competitive due to low prices, while firms assess US manufacturing, diversify export markets and reduce dependence on Chinese API supplies.
Why this matters
No related recent signals are provided; the proposed tariff timeline introduces a new risk to India’s US-focused generic-drug export model.
Retail-company signals are accelerating, up 995400% QoQ.